Although MET-selective TKIs, such as capmatinib, tepotinib, and savolitinib, have become the new standard of care for treating NSCLC, the combination of MET-TKIs and EGFR-TKIs (osimertinib plus savolitinib, tepotinib plus gefitinib) may be a potential solution for preventing MET-driven EGFR-TKI resistance. Here, MET is linked to non-small cell lung carcinoma.